Benzathine penicillin G for the management of RHD: Concerns about quality and access, and opportunities for intervention and improvement

Rosemary Wyber*, Kathryn Taubert, Stephen Marko, Edward L. Kaplan

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

52 Citations (Scopus)

Abstract

Benzathine penicillin G is an important antibiotic for the treatment and prevention of group A streptococcal infections associated with rheumatic fever and rheumatic heart disease. However, as rheumatic heart disease has receded as a public health priority in most high-income settings, attention to the supply, manufacture, and accessibility of benzathine penicillin G has declined. Concerns about the quality, efficacy, and innovation of the drug have emerged following plasma analysis and anecdotal reports from low-resource settings. This review collates core issues in supply and delivery of benzathine penicillin G as a foundation for concerted efforts to improve global quality and access. Opportunities for intervention and improvement are explored.

Original languageEnglish
Pages (from-to)227-234
Number of pages8
JournalGlobal Heart
Volume8
Issue number3
DOIs
Publication statusPublished - Sept 2013
Externally publishedYes

Fingerprint

Dive into the research topics of 'Benzathine penicillin G for the management of RHD: Concerns about quality and access, and opportunities for intervention and improvement'. Together they form a unique fingerprint.

Cite this